Multi-Cancer Early Detection Market Size, Share & Growth 2026–2035

Multi-Cancer Early Detection encompasses diagnostic tests that screen asymptomatic or higher-risk adults for signals of several cancer types in a single sample, and, in most cases, predict the tissue of origin so a positive result can be routed to the right diagnostic workup. The report scope covers liquid biopsy, genomic, epigenetic and methylation, proteomic and multi-omics technologies; blood, tissue, urine and other sample types; six cancer-type categories; and four end-user settings, from central laboratories to physician offices.

The value chain runs in three tiers. Foundational providers such as Illumina supply the sequencing and proteomic platforms most assays run on. Specialist developers — GRAIL, Exact Sciences, Guardant Health, Freenome, Harbinger Health and DELFI Diagnostics in the U.S., alongside Burning Rock Biotech, Gene Solutions, GC Genome, Mirxes and Craif in Asia Pacific — design, validate and commercialize the tests. Application-layer specialists, including Quest Diagnostics and Natera, carry testing into physician networks, phlebotomy footprints and laboratory channels at scale.

For procurement and investment decision-makers, the open question isn't whether multi-cancer screening reaches routine care — it's which technologies, cancer targets and payer channels capture value first. This report provides sub-segment data across four segmentation dimensions, country-level forecasts for 35+ geographies, and positioning analysis for 14 companies.

According to International Agency for Research on Cancer (IARC), GLOBOCAN 2022, February 2024, According to the International Agency for Research on Cancer, February 2024, there were close to 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and most of those cancers have no recommended population screening test — the gap multi-cancer early detection is built to close.

Machine learning is the engine inside most multi-cancer tests, not an add-on. GRAIL's Galleri uses a trained classifier on targeted DNA methylation patterns to detect a cancer signal and predict its tissue of origin, and DELFI Diagnostics applies machine learning to genome-wide cell-free DNA fragmentation patterns in its FirstLook Lung test. Classifier quality — trained on tens of thousands of samples — drives the specificity that keeps false-positive workups manageable.

For buyers, this shifts evaluation from the lab chemistry to the model: training-set size, population diversity and how tissue-of-origin accuracy holds up in real-world screening. Payers and regulators will increasingly ask for locked algorithms and post-market performance monitoring. Expect classifier retraining on large prospective datasets, such as NHS-Galleri and PATHFINDER 2, to become a competitive moat through 2035.

Liquid biopsy is the dominant technology at 47.0% of 2025 revenue (USD 594.3 Mn), and the reason is mostly logistical: a standard blood draw fits the phlebotomy and laboratory workflows that already exist. It's also the fastest-growing technology, compounding at 19.62% a year to reach USD 3,565.2 Mn by 2035, because every new payer pathway is being written around blood-based screening first. Guardant Health's March 2026 launch of Shield MCD across several Asian markets with Manulife shows how quickly a blood test can be distributed through an insurer channel. Multi-omics platforms (14.1%) and proteomic analysis (12.8%) are larger today than their growth suggests; both expand below 9% a year as their markers get folded into blood-based panels. Expect the technology split to concentrate further.

Lung cancer leads at 22.0% of 2025 revenue (USD 278.7 Mn), reflecting a simple gap: it kills more people than any other cancer, yet low-dose CT screening reaches only a minority of eligible smokers. It's also the fastest-growing cancer type, expanding at 21.51% a year to USD 1,955.0 Mn by 2035 as blood tests are positioned as an on-ramp to imaging. Colorectal cancer follows at an 18.65% CAGR, helped by the precedent of FDA-approved blood screening. DELFI Diagnostics' December 2025 partnership with Hackensack Meridian Health, which uses its FirstLook Lung blood test to lift screening adherence, is the template other health systems are watching. Pancreatic (16.7%) and ovarian (15.2%) cancers carry the clearest unmet need, because neither has an established screening test.

Blood-based tests hold 69.3% of 2025 revenue (USD 877.0 Mn), since cell-free DNA and protein signals are densest in plasma and a draw slots into an annual checkup. The fastest-growing sample type is tissue-based testing, expanding at a 21.14% CAGR from USD 127.8 Mn, because every positive blood screen triggers a confirmatory biopsy and pathology workup. Urine-based testing, at 11.0% of revenue, remains a niche with a strong convenience argument. Japan's Craif raised about JPY 5.3 Bn in August 2026 to take its urine-based miSignal test to the U.S., one of the few non-blood platforms still attracting late-stage capital. Over the forecast horizon, blood stays the screening sample while tissue becomes the volume engine behind positives.

Diagnostic laboratories are the largest end user at 38.8% of 2025 revenue (USD 490.4 Mn), because almost every multi-cancer test runs as a laboratory-developed test in a high-throughput CLIA-certified central lab. Academic and research institutes grow fastest, at 23.11% a year to USD 2,003.2 Mn by 2035, as large public studies such as the National Cancer Institute's Vanguard Study buy tests at research scale. Physician offices, at 21.7% share and an 18.35% CAGR, are where ordering decisions are actually made. Quest Diagnostics' June 2025 agreement to develop the MCaST blood test with MD Anderson technology shows national labs moving to own both the assay and the channel. Laboratories keep the volume, but the margin is migrating toward whoever controls the ordering physician.

Vectomat Insights estimates about 2.46 million multi-cancer early detection tests were performed worldwide in 2025, an implied average revenue of roughly USD 514 per test against USD 1,264.8 Mn of revenue. Liquid biopsy is both the volume and the value leader, at 49.5% of tests and 47.0% of revenue. The volume-value split shows up elsewhere: proteomic tests take 16.5% of volume but only 12.8% of revenue, because protein panels sell at lower prices across Asia, while multi-omics platforms carry 8.5% of tests yet 14.1% of revenue on premium pricing. GRAIL alone accounted for more than 185,000 of those tests.

The Multi-Cancer Early Detection market is concentrated at the top and fragmented underneath. GRAIL, Exact Sciences and Guardant Health account for most commercial U.S. test volume, and each pairs a blood test with a distinct route to payment — FDA approval, Abbott's commercial reach and insurer partnerships respectively. A second tier of venture- and public-market-funded developers competes on assay chemistry, from DELFI's fragmentomics to Freenome's multiomics, while Asian developers such as Gene Solutions and Mirxes compete on price. Key players include GRAIL, Exact Sciences, Guardant Health, Freenome, Natera, Illumina, Quest Diagnostics, DELFI Diagnostics, Harbinger Health, Burning Rock Biotech, Gene Solutions, GC Genome, Mirxes, and Craif, among others.

Strategic activity is converging on three themes. First, consolidation: Abbott closed its Exact Sciences acquisition in March 2026 and Natera agreed to buy Foresight Diagnostics in December 2025. Second, capital formation for evidence generation, with Freenome's July 2026 listing and Harbinger Health's USD 100 Mn raise funding large clinical studies. Third, payer-channel partnerships, such as Guardant's Manulife deal in Asia. Expect FDA-label wording, not assay chemistry, to decide market share after 2027.

Platform and Reagent Supply — Sequencing instruments, methylation chemistry, proteomic assays and bioinformatics pipelines form the technical base for almost every test. Supply is concentrated in a few platform vendors, which gives them pricing power over reagent consumables and makes sequencing cost per sample the single biggest variable in test economics. Illumina's January 2026 purchase of SomaLogic extends that concentration into protein markers, and developers building multiomics assays now depend on the same vendor for both DNA and protein reads. Key Players: Illumina.

Test Development and Clinical Validation — Developers design the assay, train classifiers on tens of thousands of samples and run the prospective studies regulators and payers demand. This is the most capital-intensive stage: NHS-Galleri enrolled about 140,000 people, and Freenome raised about USD 310 Mn in 2026 largely to fund studies. Regulatory status — LDT, Breakthrough designation or full premarket approval — determines how widely a test can be sold. Key Players: GRAIL, Freenome, Guardant Health, Gene Solutions.

Laboratory Processing and Clinical Delivery — Samples are drawn at physician offices, health-system sites or mobile phlebotomy, then shipped to CLIA-certified central laboratories for processing. Results go back to ordering physicians, who manage positive results through imaging and biopsy. National lab networks and health-system partners control this stage, which is why developers sign channel deals with insurers and labs. Turnaround time and positive-result navigation, rather than the assay itself, often decide whether a physician orders the test again. Key Players: Quest Diagnostics, Natera, Hackensack Meridian Health.

North America leads the Multi-Cancer Early Detection market with a 37.2% share, while Asia Pacific is the fastest-growing region. The split is structural: the U.S. combines laboratory-developed-test flexibility with the deepest developer funding, whereas Asia Pacific growth runs through insurers and local developers selling lower-priced tests at volume.

North America holds 37.2% of the 2025 Multi-Cancer Early Detection market (USD 470.5 Mn), the largest share of any region. The United States alone accounted for USD 395.5 Mn and is forecast to grow at a 14.9% CAGR to about USD 1,586.2 Mn by 2035. Three things concentrate demand here: the deepest venture and public-market funding for test developers, a CLIA framework that lets laboratory-developed tests reach patients before FDA approval, and the February 2026 Nancy Gardner Sewell Act, which gives Medicare a payment route once a test is approved. GRAIL's Galleri, Exact Sciences' Cancerguard and Guardant Health's Shield MCD are all sold in the U.S. today. Canada contributes smaller, trial-led demand. Self-pay pricing remains the region's main brake, and the U.S. is set to quadruple to roughly USD 1.6 Bn by 2035.

Europe holds 25.5% of global revenue in 2025 (USD 322.5 Mn). Germany is the largest national market at USD 94.2 Mn, forecast to grow at a 14.2% CAGR to about USD 355.4 Mn by 2035, supported by a dense private-laboratory sector and early self-pay uptake. The U.K. carries outsized influence relative to its size because NHS England ran the world's largest randomized MCED study. Its full results, presented at ASCO in June 2026, showed fewer stage IV diagnoses but missed the trial's primary stage III–IV endpoint, which leaves national payers cautious. The EU's In Vitro Diagnostic Regulation adds certification cost for every new assay. Europe's adoption will be set less by test performance than by health-technology-assessment bodies, and the NHS-Galleri readout is the evidence every one of them is now weighing.

Asia Pacific is the fastest-growing region and already holds 25.7% of 2025 revenue (USD 325.1 Mn), narrowly ahead of Europe. Japan is the largest country market at USD 98.8 Mn, growing at a 15.9% CAGR to about USD 432.1 Mn by 2035, while South Korea is the fastest-growing tracked country at 17.9%. The region's growth model is different: insurers and home-grown developers, not Medicare-style payers, are driving uptake. Guardant Health launched Shield MCD across several Asian markets through Manulife in March 2026, and Gene Solutions, Burning Rock Biotech, GC Genome, Mirxes and Craif all sell or validate tests locally at lower price points. Uneven regulation across national authorities is the main obstacle. Structurally, Asia Pacific is where multi-cancer screening becomes a high-volume, insurer-bundled consumer product rather than a physician-ordered specialty test.

Latin America accounts for 5.3% of the 2025 market (USD 67.0 Mn), with Brazil leading demand through private hospital networks and premium health plans in São Paulo and Rio de Janeiro. Most samples are still sent to U.S. or European central laboratories, adding cost and turnaround time, and ANVISA registration remains a prerequisite for broader commercial launch. Uptake is concentrated among affluent, privately insured adults. As regional laboratory partners license assays rather than export samples, Latin America should grow steadily through 2035.

The Middle East holds 3.1% of 2025 revenue (USD 39.2 Mn). GCC markets — led by Saudi Arabia and the UAE — are the main buyers, folding advanced screening into preventive-health and national genomics programs, while Israel adds research-led demand through its academic medical centers. The region imports nearly all of its tests and has limited local sequencing capacity, which keeps per-test costs high. Gulf private hospitals still drive demand from a small base, and the region's share should hold near 3.1% through the forecast period.

Africa represents 3.2% of the 2025 market (USD 40.5 Mn), with South Africa and Egypt the leading countries. Demand comes mainly from private laboratory groups and insured urban patients, since public screening budgets focus on cervical, breast and colorectal programs with proven protocols. Weak diagnostic follow-up capacity for positive results is the region's biggest structural constraint. Private pathology networks such as Lancet Laboratories and Ampath in South Africa are the logical channels for carrying imported tests to patients.

Reimbursement/funding initiative — The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, signed into law in February 2026, directs Medicare to cover FDA-approved multi-cancer tests, turning a self-pay category into a payer-funded one for tens of millions of older Americans. (Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act)

Public health screening program — NHS England's NHS-Galleri trial enrolled roughly 140,000 adults to test whether annual multi-cancer screening reduces late-stage diagnoses, and its 2026 results now anchor European reimbursement debates. (NHS-Galleri trial)

Government-funded clinical research network — The U.S. National Cancer Institute's Cancer Screening Research Network launched the Vanguard Study in 2025 to evaluate multi-cancer detection tests in up to 24,000 participants, building the independent evidence base payers want. (NCI Cancer Screening Research Network Vanguard Study)

Regulatory-approval program — FDA's Breakthrough Devices Program has granted designations to several multi-cancer tests, including Gene Solutions' SPOT-MAS 10 in July 2026, giving developers prioritized review interactions ahead of premarket submissions. (FDA Breakthrough Devices Program)

Activity since early 2026 has clustered around regulatory milestones and capital formation, as developers race to secure FDA approval, Medicare coverage and the funding to run large clinical studies.